These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21314492)

  • 21. Motor complications, levodopa metabolism and progression of Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):847-55. PubMed ID: 21480824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.
    Gunay MS; Ozer AY; Chalon S
    Curr Neuropharmacol; 2016; 14(4):376-91. PubMed ID: 26714584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of motor symptoms in Parkinson's disease].
    Morís-De la Tassa G; Arias-Rodríguez M
    Rev Neurol; 2009 Jan; 48 Suppl 1():S27-31. PubMed ID: 19222012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine therapy in Parkinson's and future directions.
    Titova N; Chaudhuri KR
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S56-S60. PubMed ID: 27913125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New concepts in the treatment of Parkinson's disease.
    Ahlskog JE; Wilkinson JM
    Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.
    Reese JP; Dams J; Winter Y; Balzer-Geldsetzer M; Oertel WH; Dodel R
    Expert Opin Pharmacother; 2012 May; 13(7):939-58. PubMed ID: 22475391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Parkinson's disease a review of current and new therapies.
    Mendis T; Suchowersky O; Lang A; Gauthier S
    Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapies for Parkinson's disease.
    Poewe W; Mahlknecht P; Jankovic J
    Curr Opin Neurol; 2012 Aug; 25(4):448-59. PubMed ID: 22772874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on the treatment of Parkinson's disease.
    Jankovic J
    Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 35. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
    Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
    J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.